CA3041832A1 - Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways - Google Patents

Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways Download PDF

Info

Publication number
CA3041832A1
CA3041832A1 CA3041832A CA3041832A CA3041832A1 CA 3041832 A1 CA3041832 A1 CA 3041832A1 CA 3041832 A CA3041832 A CA 3041832A CA 3041832 A CA3041832 A CA 3041832A CA 3041832 A1 CA3041832 A1 CA 3041832A1
Authority
CA
Canada
Prior art keywords
alkyl
halogen
alkoxy
amine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3041832A
Other languages
English (en)
French (fr)
Inventor
Claus Scheidereit
Michael WILLENBROCK
Peter Lindemann
Silke RADETZKI
Jens Peter VON KRIES
Marc Nazare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Forschungsverbund Berlin FVB eV
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Forschungsverbund Berlin FVB eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft, Forschungsverbund Berlin FVB eV filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of CA3041832A1 publication Critical patent/CA3041832A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3041832A 2016-11-14 2017-11-14 Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways Pending CA3041832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16198731.8 2016-11-14
EP16198731.8A EP3321264A1 (en) 2016-11-14 2016-11-14 Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
PCT/EP2017/079181 WO2018087389A1 (en) 2016-11-14 2017-11-14 SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS

Publications (1)

Publication Number Publication Date
CA3041832A1 true CA3041832A1 (en) 2018-05-17

Family

ID=57288311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3041832A Pending CA3041832A1 (en) 2016-11-14 2017-11-14 Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways

Country Status (7)

Country Link
US (1) US11028084B2 (https=)
EP (2) EP3321264A1 (https=)
JP (2) JP7307677B2 (https=)
CN (1) CN109963850A (https=)
AU (1) AU2017359276B2 (https=)
CA (1) CA3041832A1 (https=)
WO (1) WO2018087389A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
CN113913515A (zh) * 2020-07-10 2022-01-11 上海吉凯基因医学科技股份有限公司 人eme1基因的用途及相关产品
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
US20240067654A1 (en) * 2020-12-14 2024-02-29 Kinoxis Therapeutics Pyt Ltd Oxytocin receptor modulators
WO2024129715A1 (en) * 2022-12-13 2024-06-20 Flare Therapeutics Inc. Compounds and composition for targeting tp53-y220c mutants
EP4467141A1 (en) 2023-05-24 2024-11-27 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Pyrazolo-quinolines as selective inhibitors of genotoxic stress-induced ikk/nf- kb pathways for cancer therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663559A (en) * 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
CN100503607C (zh) * 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
EP1989203A2 (en) * 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
TW200800978A (en) * 2006-03-23 2008-01-01 Otsuka Pharma Co Ltd Carbazole compound
JP5583592B2 (ja) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
AU2009228034A1 (en) * 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
US8431538B2 (en) * 2009-07-22 2013-04-30 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods of using same
DE112010005017A5 (de) * 2009-12-28 2012-10-04 Audiocure Pharma Gmbh Beta-carboline zur behandlung von hörschäden und schwindel
CN102146080B (zh) * 2010-02-10 2013-01-30 新疆华世丹药业股份有限公司 β-咔啉碱衍生物类化合物及其应用
US20120039804A1 (en) * 2010-06-04 2012-02-16 Philippe Diaz Novel Tricyclic Modulators of Cannabinoid Receptors
CN103070862A (zh) * 2011-10-25 2013-05-01 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物在制备抗菌药物中的应用
WO2013064460A1 (en) * 2011-11-02 2013-05-10 Bayer Intellectual Property Gmbh Compounds with nematicidal activity
EP2895462A1 (en) * 2012-09-13 2015-07-22 Baden-Württemberg Stiftung gGmbH Specific inhibitors of protein p21 as therapeutic agents
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways

Also Published As

Publication number Publication date
EP3538529B1 (en) 2022-01-19
JP2023101521A (ja) 2023-07-21
US11028084B2 (en) 2021-06-08
EP3538529A1 (en) 2019-09-18
US20190276452A1 (en) 2019-09-12
JP2019535709A (ja) 2019-12-12
JP7701403B2 (ja) 2025-07-01
AU2017359276A1 (en) 2019-05-16
CN109963850A (zh) 2019-07-02
EP3321264A1 (en) 2018-05-16
WO2018087389A1 (en) 2018-05-17
JP7307677B2 (ja) 2023-07-12
AU2017359276B2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
EP3538529B1 (en) Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
US12269820B2 (en) Piperazine substituted indazole compounds as inhibitors of PARG
Gupta et al. Spiro-oxindoles as a promising class of small molecule inhibitors of p53–MDM2 interaction useful in targeted cancer therapy
Michels et al. Predictive biomarkers for cancer therapy with PARP inhibitors
Zhang et al. Discovery of 4-hydroxyquinazoline derivatives as small molecular BET/PARP1 inhibitors that induce defective homologous recombination and lead to synthetic lethality for triple-negative breast cancer therapy
ES2293068T3 (es) Imidazopiridinas como inhibidores de quinasas dependientes de ciclina.
KR20220035925A (ko) Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
WO2018133795A1 (zh) 一种ezh2抑制剂及其用途
CN103242341A (zh) 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
CN102083314A (zh) Parp抑制剂化合物、组合物以及使用方法
CN103237799A (zh) 杂环衍生物、制备方法及其药学用途
CN107531665A (zh) Egfr和pi3k的小分子抑制剂
CN110603256A (zh) 可用作wee-1激酶抑制剂的嘧啶并嘧啶酮
KR20180035905A (ko) Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
TW200412966A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2018236971A1 (en) Single molecule compounds providing multi-target inhibition of parp and other proteins and methods of use thereof
EP3440070B1 (en) Mdr-reversing 8-hydroxy-quinoline derivatives
Byrne et al. Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma
HK40015060A (en) SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS
HK40015060B (en) SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS
EP4467141A1 (en) Pyrazolo-quinolines as selective inhibitors of genotoxic stress-induced ikk/nf- kb pathways for cancer therapy
US20210353631A1 (en) 1,4-Benzoxazines for the Treatment of Cancers and Other Neurodegenerative Diseases
CN103893182A (zh) 一类set蛋白小分子抑制剂及其用途
Guan et al. Discovery of Novel Heterotetracyclic DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Improved Oral Bioavailability and Potent Cancer Immunotherapy-Potentiating Activity
Harnor et al. Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241105

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241105

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241129

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250403

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250710

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250710

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251218